While targeting VM has just started to emerge as a therapeutic strategy for cancer, there are currently no clinical trials testing direct YAP/TAZ inhibitors as transcriptional coactivators are difficult to target and possibly toxic [90]. The gene discussed is YAP1; the disease is cancer.